Executive Chairman LoPriore's Group Boosts Stake to 26.2% with $500K July Purchase
CTRVP is trading near its 52-week low of $0.001 (0.0% above the low).
Summary
Executive Chairman Vincent LoPriore and his affiliated entities increased their stake in Hepion Pharmaceuticals to 26.2% through a $500,000 purchase of shares and warrants on July 31, 2026.
Key Events · Ownership and Investor Activity · CTRVP
-
LoPriore Group Raises Stake to 26.2%
Vincent LoPriore, Executive Chairman, and his affiliated entities Gravitas Capital LP and Invictus Capital Advisors Pension Plan now beneficially own 26,250,000 shares, or 26.2% of Hepion Pharmaceuticals' outstanding common stock.
-
July 31 Acquisitions Total $500,000
Gravitas acquired 8,000,000 shares and a warrant for 8,000,000 shares for $400,000; Invictus acquired 2,000,000 shares and a warrant for 2,000,000 shares for $100,000.
-
Warrants Exercisable at $0.06
The warrants are immediately exercisable at $0.06 per share, subject to a Beneficial Ownership Limitation, potentially adding 10,000,000 shares to LoPriore's holdings.
-
Insider Buying Cluster
This filing follows Form 4 disclosures on August 13, 2026, showing purchases by the Executive Chairman, COO, and directors in the company's recent private placement, indicating broad insider support.
Analysis · CTRVP · Life Sciences
Vincent LoPriore, Executive Chairman of Hepion Pharmaceuticals, and his affiliated entities Gravitas Capital LP and Invictus Capital Advisors Pension Plan, increased their combined beneficial ownership to 26.2% of the company's common stock. The amendment discloses that on July 31, 2026, Gravitas acquired 8 million shares and a warrant for 8 million shares for $400,000, and Invictus acquired 2 million shares and a warrant for 2 million shares for $100,000. The warrants are immediately exercisable at $0.06 per share. This brings LoPriore's aggregate beneficial ownership to 26.25 million shares, including 10 million shares underlying warrants. The filing follows a series of insider purchases in the company's recent private placement, signaling strong insider conviction despite the company's going concern warning and low stock price.
At the time of this filing, CTRVP was trading at $0.00 on OTC in the Life Sciences sector, with a market capitalization of approximately $6.8M. The 52-week trading range was $0.00 to $0.00. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.